Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment

DISEASE CHARACTERISTICS: * Histologically confirmed refractory solid tumor for which no curative standard therapy exists * Metastatic disease * Treated brain metastases that have been stable ≥ 3 months allowed * At least 1 week since prior steroids PATIENT CHARACTERISTICS: * ECOG performance status of 0-1 * ANC ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Creatinine ≤ 2 times upper limit of normal (ULN) * ALT and AST ≤ 5 times ULN * Total bilirubin ≤ 1.5 mg/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No serious concurrent infection or medical illness that would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety * No prior or other concurrent malignancy except for curatively treated carcinoma-in-situ at any site or basal cell carcinoma or squamous cell carcinoma of the skin * Patients who have been free of disease (any prior malignancy) for ≥ 5 years are eligible * No porphyria * No psoriasis, except well controlled psoriasis under the care of a specialist * No previously documented macular degeneration or diabetic retinopathy * No HIV positivity PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Any number and type of prior anticancer therapies allowed * No prior mTOR inhibitors * At least 4 weeks since prior immunotherapy (i.e., aldesleukin, interferon, CTLA-4) or chemotherapy and recovered * At least 2 weeks since prior oral targeted therapy and recovered * At least 4 weeks since prior and no other concurrent investigational anticancer therapy (except for vaccines) * No other concurrent therapy * No concurrent combination antiretroviral therapy for HIV-positive patients * No concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs (i.e., phenytoin, carbamazepine, phenobarbital, primidone, or oxcarbazepine) * Concurrent non-enzyme inducing anticonvulsants, including felbamate, valproic acid, gabapentin, lamotrigine, tiagabine, topiramate, zonisamide, or levetiracetam allowed * Concurrent hematologic growth factors (filgrastim \[G-CSF\], pegfilgrastim, epoetin alfa) allowed in patients with severe myelosuppression